Route 92 Medical has announced its expansion to a new high-volume manufacturing site in Salt Lake City, USA. This 40,000-square-foot site will allow Route 92 to substantially augment its manufacturing capabilities while serving as a clinician training and education centre, the company claims in a press release.
Route 92 will maintain its California headquarters in San Mateo, USA, sustaining its existing product manufacturing capabilities, and research and development centre for the design and production of new products.
“At Route 92 Medical, we are not only planning for the successful completion of our SUMMIT MAX pivotal trial, but also investing to scale our platform and teams over time,” said Tony Chou, founder and CEO of Route 92. “Our new facility allows us to increase production of our proprietary Monopoint operating platform and HiPoint 88 super-bore catheter. The alternate location will add a critical training centre and allow us to reach more clinician users. Having a second home base for attracting additional talent is all in support of our long-term growth strategy.
“Our platform’s clinical performance has suggested a remarkable first-pass effect in the treatment of acute ischaemic stroke in multiple initial publications to date. Buoyed by our product performance, we are ensuring that we have the foundation in place to support the broader use of our solutions to improve patient outcomes in neurointervention over the years ahead.”
